<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887887</url>
  </required_header>
  <id_info>
    <org_study_id>08-4-022</org_study_id>
    <nct_id>NCT00887887</nct_id>
  </id_info>
  <brief_title>The Association Between Gene Polymorphisms and Infectious Complications After Liver Surgery</brief_title>
  <official_title>The Association Between Gene Polymorphisms in the Innate Immune Response and the Risk of Infectious Complications and Liver Failure After Partial Hepatic Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test whether the presence of polymorphisms in genes encoding&#xD;
      substances of the innate immune response in patients undergoing partial hepatic resection&#xD;
      because of benign or malignant hepatobiliary disease is related to a higher incidence of&#xD;
      infectious complications, post-resectional liver failure or mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Partial hepatic resection is a feasible and relatively safe procedure for selected patients&#xD;
      with benign or malignant hepatobiliary disease. Liver failure after partial hepatic&#xD;
      resection, so-called post-resectional liver failure (PLF), is a dreaded complication with&#xD;
      high mortality rates. Patients suffering from PLF experience significantly more clinically&#xD;
      significant infections (CSI) when compared with patients without PLF. The liver plays an&#xD;
      important role in the body's innate immune defense. Recently, polymorphisms in genes encoding&#xD;
      key molecules in the innate immune response (e.g. nuclear factor kappa-B) have shown to be&#xD;
      associated with a greater risk of CSI. The presence of these polymorphisms combined with&#xD;
      partial hepatic resection might render patients susceptible to the development of CSI, PLF&#xD;
      and early mortality after liver resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinically significant infectious complications (i.e. wound infection, pneumonia, blood stream infection, gastro-intestinal infection, intra-abdominal infection, urinary tract infection and miscellaneous)</measure>
    <time_frame>90 days after liver surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-resectional liver failure</measure>
    <time_frame>90 days after liver surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90 days after liver surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>liver surgery</arm_group_label>
    <description>patients with benign or malignant hepatobiliary disease requiring partial hepatic resection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, fresh frozen liver tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with benign or malignant liver disease requiring partial hepatic resection at the&#xD;
        Maastricht University Medical Centre&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  benign or malignant liver disease requiring partial hepatic resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to give informed consent&#xD;
&#xD;
          -  liver disease judged irresectable after intra-operative evaluation&#xD;
&#xD;
          -  use of immunosuppressive drugs&#xD;
&#xD;
          -  resection &lt; 1 segment&#xD;
&#xD;
          -  unable to comply with follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven WM Olde Damink, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver surgery</keyword>
  <keyword>gene polymorphisms</keyword>
  <keyword>innate immune response</keyword>
  <keyword>infectious complications</keyword>
  <keyword>post-resectional liver failure</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

